Imatinib induced bone marrow hypoplasia in a case of chronic myelogenous leukemia

Mehlam Kausar; Shashidhar V. Karpurmath; Manjunath I. Nandennavar; Roshan K. Jacob; Veerendra Angadi; Annalakshmi Sekar

doi:10.18203/2320-6012.ijrms20190371

Authors

Mehlam Kausar Department of Medical Oncology, Vydehi Institute of Medical Sciences and Research Institute, Bengaluru, Karnataka, India
Shashidhar V. Karpurmath Department of Medical Oncology, Vydehi Institute of Medical Sciences and Research Institute, Bengaluru, Karnataka, India
Manjunath I. Nandennavar Department of Medical Oncology, Vydehi Institute of Medical Sciences and Research Institute, Bengaluru, Karnataka, India
Roshan K. Jacob Department of Medical Oncology, Vydehi Institute of Medical Sciences and Research Institute, Bengaluru, Karnataka, India
Veerendra Angadi Department of Medical Oncology, Vydehi Institute of Medical Sciences and Research Institute, Bengaluru, Karnataka, India
Annalakshmi Sekar Department of Medical Oncology, HCG hospital, Bengaluru, Karnataka, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20190371

Keywords:

Bone Marrow, CML, Hypoplasia, Imatinib

Abstract

Imatinib mesylate a tyrosine kinase inhibitor first introduced for the treatment of chronic myelogenous leukaemia (CML) since May 2001, has revolutionised the management of CML. Imatinib is the first choice of treatment for patient with CML chronic phase (CML-CP) and generally the drug is well tolerated. A number of haematological and non-haematological side effects are associated with it. Bone marrow hypoplasia is one of the rare side effects noted with imatinib. We report a case of 46-year-old male a case of CML-CP who developed bone marrow hypoplasia following treatment with imatinib for a period of six months with bone marrow biopsy showing decreased cellularity.

Metrics

Metrics Loading ...

References

Rumpold H, Webersinke G. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia-is it all BCR-ABL? Curr Cancer Drug Targets. 2011;11:3-19

Hasserjian RP, Boecklin F, Parker S, Chase A, Dhar S, Zaiac M, et al. STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol. 2002;117(3):360-7.

Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-82.

O'brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia. N Engl J Med. 2003;348(11):994-1004.

Hasserjian RP, Boecklin F, Parker S, Chase A, Dhar S, Zaiac M, et al. STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. American J Clin Pathol. 2002 Mar 1;117(3):360-7.

Paul TR, Uppin SG, Uppin MS, Jacob RT, Rao DR, Rajappa SJ. Evaluation of cytopenias occurring in imatinib treated chronic myeloid leukemia (CML) patients. Ind J Hematol Blood Trans. 2010 Jun 1;26(2):56-61.

Srinivas U, Pillai LS, Kumar R, Pati HP, Saxena R. Bone marrow aplasia-a rare complication of imatinib therapy in CML patients. Am J Hematol. 2007;82:314-31.

Lokeshwar N, Kumar L, Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma. 2005;46:781-4.

Mauro MJ, O’Dwyer ME, Kurilik G, Blasdel C, Farnswort M, Fong D, et al. Risk factors for myelosuppression in chronic phase CML patients treated with imatinib mesylate. Blood. 2001;98(Suppl 1):139a.

Sneed TB, Kantarjian HM, Talpaz M, O’Brien S, Rios MB, Bekele BN, et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer. 2004;100:116-21.